SecBot SecBot
144 ·Filed Oct 30, 2026

LGND

LIGAND PHARMACEUTICALS INC
NEUTRAL
Impact 2/10
Horizonimmediate Processed17d 8h ago SEC0001950047-26-010515
Form 144: notice of proposed sale of securities
Actionable Insight • Neutral

The proposed sale is very small relative to the insider's total holdings and market cap. Monitor the insider's Form 4 filings to see if the sale was actually executed; a single small sale by a director is routine and not a signal of deteriorating fundamentals.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$307.02
T+0 close · Oct 30, 2026 · via day close
Latest settled
+2.32%
T+5 · $314.15 · next T+20 in 14d
Vs SPY
+2.24%
α at T+5
Latest observation
+0.79%
T+9 · FF3 residual α
  1. T+0 · Nov 2 $307.02entry
  2. T+1 · 14d ago +2.12%α +1.82% · $313.52
  3. T+5 · 8d ago +2.32%α +2.24% · $314.15
  4. T+10 · todayOpen
  5. T+20 · in 14d Pending
  6. T+60 · in 2mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Director Jason Aryeh filed a Form 144 notice of intent to sell 1,209 shares of Ligand Pharmaceuticals common stock, valued at approximately $385,185 based on the filing date. The shares were acquired as restricted stock on June 5, 2026, and the proposed sale is scheduled for October 30, 2026. This is a small, routine sale by a director and carries minimal signal value.

Key Facts

  • Jason Aryeh, a Director of Ligand Pharmaceuticals, filed Form 144 to sell 1,209 shares of common stock.
  • The approximate market value of the proposed sale is $385,185.
  • The shares were acquired as restricted stock on June 5, 2026.
  • The proposed sale date is October 30, 2026.
  • The sale represents about 0.006% of the company's $6.4B market cap.

Financial Impact

Proposed sale of 1,209 shares valued at approximately $385,185, representing a negligible fraction of the company's market cap.

dilution

Risk Factors

  • Form 144 is an advance notice of intent to sell; the sale may not be executed.
  • No other insider selling pattern or context provided to suggest a pattern.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
94% bullish (17 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001950047-26-010515
Document: 0001950047-26-010515-index.html0001950047-26-010515
Document: 0001950047-26-010515.txt0001950047-26-010515

US Market Status

Market Closed · Opens in 8h 59m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Oct 30, 2026